{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:23:53Z","timestamp":1790051033713,"version":"4.0.1"},"reference-count":50,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32460190"],"award-info":[{"award-number":["32460190"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960547"],"award-info":[{"award-number":["81960547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060639"],"award-info":[{"award-number":["82060639"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Science and Technology Special Fund of Hainan Province","award":["ZDKJ202003"],"award-info":[{"award-number":["ZDKJ202003"]}]},{"name":"The Science and Technology Special Fund of Hainan Province","award":["ZDYF2022SHFZ287"],"award-info":[{"award-number":["ZDYF2022SHFZ287"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,1,20]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Enhancing antigen cross-presentation is essential for the development of a tumor neoantigen vaccine. One approach is to stimulate antigen-presenting cells (APCs) to uptake neoantigens. <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (MTb) contains pathogen-associated molecular patterns (PAMPs) recognized by APCs and adhesion molecules that facilitate MTb invasion of APCs. Therefore, we suggest using MTb as a carrier to enhance APC phagocytosis of neoantigens, thereby promoting antigen cross-presentation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The successful preparation of the MTb carrier (phMTb) was confirmed through electron and confocal microscopy. Fluorescence microscopy was used to detect PAMPs and adhesion molecules on phMTb as well as to observe its role in aiding dendritic cells (DCs) in antigen uptake into endosomes or lysosomes. Flow cytometry was used to assess the retention of PAMPs and adhesion molecules on phMTb, investigate antigen uptake by DCs, evaluate their activation and maturation status, examine the presentation of tumor neoantigens, and analyze immune cells in draining lymph nodes and tumor tissues. The efficacy of phMTb vaccine formulations in combination with anti-programmed cell death protein 1 (PD-1) antibody therapy was assessed using the MC38 mouse tumor models. Adverse effects were evaluated through H&amp;E staining of major organs, assessment of reproductive capability and detection of biochemical indices.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The engineered porous hollow phMTb carrier successfully encapsulated model tumor neoantigens, with or without the adjuvant CpG. The phMTb retained PAMPs and adhesion molecules on its surface, similar to the parental MTb, thereby enhancing DC uptake of phMTb and its formulations containing tumor neoantigens and CpG. Vaccines formulated with phMTb facilitated DC maturation, activation, cross-presentation of tumor neoantigens, and promoted migration of phMTb-laden DCs to lymph nodes, enhancing effector and memory CD8<jats:sup>+<\/jats:sup> T lymphocyte function. In murine tumor models, immunization with phMTb-formulated neoantigen vaccines elicited a robust tumor-specific cytotoxic T lymphocyte immune response with minimal adverse effects. Additionally, vaccination with phMTb-formulated neoantigen vaccines effectively reversed the tumor\u2019s immune-suppressive microenvironment. Concurrent administration of the PD-1 antibody with the phMTb-formulated neoantigen vaccine exhibited significant synergistic therapeutic effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of our study highlight the potential clinical translation of personalized tumor neoantigen vaccines using the phMTb carrier.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-010150","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:35:27Z","timestamp":1738820127000},"page":"e010150","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2462-841X","authenticated-orcid":false,"given":"Ming-Hui","family":"Chen","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9624-1911","authenticated-orcid":false,"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[{"name":"Public Research Center, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9637-3992","authenticated-orcid":false,"given":"Hengyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4094-4086","authenticated-orcid":false,"given":"Ri-Hong","family":"Wu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Xie","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-6831","authenticated-orcid":false,"given":"Shu-Zhen","family":"Dai","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-0457","authenticated-orcid":false,"given":"Wu-Ping","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6406-0331","authenticated-orcid":false,"given":"Guang-Hong","family":"Tan","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China"},{"name":"Department of Breast and Thyroid Surgery, The Second Affiliated Hospital, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2025100310335367000_13.2.e010150.1","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1039\/D3CS00162H","article-title":"Advancing nanotechnology for neoantigen-based cancer theranostics","volume":"53","author":"Zou","year":"2024","journal-title":"Chem Soc Rev"},{"key":"2025100310335367000_13.2.e010150.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01206-4"},{"key":"2025100310335367000_13.2.e010150.3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/CM9.0000000000002181","article-title":"Neoantigens in precision cancer immunotherapy: from identification to clinical applications","volume":"135","author":"Zhang","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"2025100310335367000_13.2.e010150.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y"},{"key":"2025100310335367000_13.2.e010150.5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134915"},{"key":"2025100310335367000_13.2.e010150.6","doi-asserted-by":"crossref","first-page":"102215","DOI":"10.1016\/j.coi.2022.102215","article-title":"Bioinspired vaccines to enhance MHC class-I antigen cross-presentation","volume":"77","author":"Baljon","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"2025100310335367000_13.2.e010150.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.03.037"},{"key":"2025100310335367000_13.2.e010150.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.09.006"},{"key":"2025100310335367000_13.2.e010150.9","doi-asserted-by":"crossref","first-page":"101848","DOI":"10.1016\/j.smim.2023.101848","article-title":"Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy","volume":"71","author":"Moussion","year":"2024","journal-title":"Semin Immunol"},{"key":"2025100310335367000_13.2.e010150.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00707-2"},{"key":"2025100310335367000_13.2.e010150.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2019.12.005"},{"key":"2025100310335367000_13.2.e010150.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.09.006"},{"key":"2025100310335367000_13.2.e010150.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02379","article-title":"Pattern Recognition Receptors and the Host Cell Death Molecular Machinery","volume":"9","author":"Amarante-Mendes","year":"2018","journal-title":"Front Immunol"},{"key":"2025100310335367000_13.2.e010150.14","doi-asserted-by":"crossref","unstructured":"Huang F-Y , Dai S-Z , Wang J-Y , et al . Engineered porous\/hollow Burkholderia pseudomallei loading tumor lysate as a vaccine. Biomaterials 2021;278. doi:10.1016\/j.biomaterials.2021.121141","DOI":"10.1016\/j.biomaterials.2021.121141"},{"key":"2025100310335367000_13.2.e010150.15","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201700083","article-title":"Biomimetically Engineered Demi-Bacteria Potentiate Vaccination against Cancer","volume":"4","author":"Ni","year":"2017","journal-title":"Adv Sci (Weinh)"},{"key":"2025100310335367000_13.2.e010150.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2018.02.012"},{"key":"2025100310335367000_13.2.e010150.17","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3346"},{"key":"2025100310335367000_13.2.e010150.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2019.126392"},{"key":"2025100310335367000_13.2.e010150.19","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.3.463-496.2003"},{"key":"2025100310335367000_13.2.e010150.20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003950","article-title":"Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3\u03b1 Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100310335367000_13.2.e010150.21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5740\/jaoacint.11-013","article-title":"New role of antibody in bacterial isolation","volume":"95","author":"Xiao","year":"2012","journal-title":"J AOAC Int"},{"key":"2025100310335367000_13.2.e010150.22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jconrel.2021.02.029","article-title":"A biotin-avidin-system-based virus-mimicking nanovaccine for tumor immunotherapy","volume":"332","author":"Lu","year":"2021","journal-title":"J Control Release"},{"key":"2025100310335367000_13.2.e010150.23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000330","article-title":"A recombinant oncolytic Newcastle virus expressing MIP-3\u03b1 promotes systemic antitumor immunity","volume":"8","author":"Huang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100310335367000_13.2.e010150.24","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.biomaterials.2015.02.123","article-title":"Microencapsulation of tumor lysates and live cell engineering with MIP-3\u03b1 as an effective vaccine","volume":"53","author":"Huang","year":"2015","journal-title":"Biomaterials"},{"key":"2025100310335367000_13.2.e010150.25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02393","article-title":"Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications","volume":"10","author":"Fucikova","year":"2019","journal-title":"Front Immunol"},{"key":"2025100310335367000_13.2.e010150.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025100310335367000_13.2.e010150.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00741-5"},{"key":"2025100310335367000_13.2.e010150.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19973-6"},{"key":"2025100310335367000_13.2.e010150.29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715234"},{"key":"2025100310335367000_13.2.e010150.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0685"},{"key":"2025100310335367000_13.2.e010150.31","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782"},{"key":"2025100310335367000_13.2.e010150.32","doi-asserted-by":"crossref","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","article-title":"Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"2025100310335367000_13.2.e010150.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2025100310335367000_13.2.e010150.34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature New Biol"},{"key":"2025100310335367000_13.2.e010150.35","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4RI0214-090R"},{"key":"2025100310335367000_13.2.e010150.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9"},{"key":"2025100310335367000_13.2.e010150.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9"},{"key":"2025100310335367000_13.2.e010150.38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/JLB.5MR1120-778R","article-title":"TCF-1 maintains CD8+ T cell stemness in tumor microenvironment","volume":"110","author":"Wen","year":"2021","journal-title":"J Leukoc Biol"},{"key":"2025100310335367000_13.2.e010150.39","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.celrep.2018.01.072","article-title":"Suppression of Tcf1 by Inflammatory Cytokines Facilitates Effector CD8 T Cell Differentiation","volume":"22","author":"Danilo","year":"2018","journal-title":"Cell Rep"},{"key":"2025100310335367000_13.2.e010150.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00810-3"},{"key":"2025100310335367000_13.2.e010150.41","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-019-00232-2"},{"key":"2025100310335367000_13.2.e010150.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y"},{"key":"2025100310335367000_13.2.e010150.43","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14069"},{"key":"2025100310335367000_13.2.e010150.44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-Associated Macrophages in Tumor Immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"2025100310335367000_13.2.e010150.45","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121559"},{"key":"2025100310335367000_13.2.e010150.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010"},{"key":"2025100310335367000_13.2.e010150.47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1860"},{"key":"2025100310335367000_13.2.e010150.48","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy: Results From the Phase I\/IIa RELATIVITY-020 Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100310335367000_13.2.e010150.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.053"},{"key":"2025100310335367000_13.2.e010150.50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw6071","article-title":"A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer","volume":"6","author":"Ni","year":"2020","journal-title":"Sci Adv"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:34:07Z","timestamp":1759512847000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,6]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/jitc-2024-010150"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010150","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}